JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

147.08

+0.55%↑

Kodu・Aktsiate loetelu・Alkermes PLC

Alkermes PLC

Avatud

SektorTervishoid

30.23 -3.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

29.88

Max

31.32

Põhinäitajad
By Trading Economics
Sissetulek	65M 87M
Müük	84M 391M
P/E Sektori keskmine	14.613 37.461
Kasumimarginaal	22.295
Töötajad	1,800
EBITDA	99M 113M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+29.09% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	28. okt 2025

Turustatistika
By TradingEconomics
Turukapital	802M 5.1B
Eelmine avamishind	33.49
Eelmine sulgemishind	30.23

Uudiste sentiment

By Acuity

50%

168 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

27.95 / 30.91 Toetus ja vastupanu

Alkermes PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. okt 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22. okt 2025, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22. okt 2025, 21:20 UTC

Tulu

Correction to IBM 3Q Sales Jump Article

22. okt 2025, 20:57 UTC

Tulu

SAP Posts Higher 3Q Revenue, Operating Profit

22. okt 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22. okt 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. okt 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. okt 2025, 23:15 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22. okt 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22. okt 2025, 22:02 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22. okt 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22. okt 2025, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22. okt 2025, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22. okt 2025, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22. okt 2025, 21:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22. okt 2025, 21:47 UTC

Tulu

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. okt 2025, 21:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22. okt 2025, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22. okt 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22. okt 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22. okt 2025, 21:28 UTC

Market Talk

Tulu

Correction to Alcoa Tariff Market Talk

22. okt 2025, 21:25 UTC

Tulu

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22. okt 2025, 21:17 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22. okt 2025, 21:09 UTC

Market Talk

Tulu

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22. okt 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22. okt 2025, 20:59 UTC

Tulu

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. okt 2025, 20:51 UTC

Tulu

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. okt 2025, 20:44 UTC

Tulu

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Võrdlus sarnastega

Hinnamuutus

Alkermes PLC Prognoos

Hinnasiht

By TipRanks

29.09% tõus

12 kuu keskmine prognoos

Keskmine 40.6 USD 29.09%

Kõrge 47 USD

Madal 33 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Alkermes PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Alkermes PLC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

27.95 / 30.91Toetus ja vastupanu

Bullish events outweigh bearish events.

All events are bearish.

All events are bullish.

Sentiment

By Acuity

168 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.